Literature DB >> 23551674

Why an apheresis center should offer more than one lipoprotein apheresis method.

Ulrich Julius1, Sabine Fischer, Ulrike Schatz, Jens Passauer, Stefan Bornstein.   

Abstract

We describe our experience with the performance of six lipoprotein apheresis methods (HELP, TheraSorb LDL, DALI, lipidfiltration, Liposorber D, MONET) which have been used in 68 patients. Thirty-four of them have been treated with more than one method. The calculations presented in this paper are based on laboratory data measured at the last three available apheresis sessions before the switch to another method and at the end of the observation period, respectively. With respect to the reduction of low-density lipoprotein (LDL) cholesterol, DALI and Liposorber D appeared to be the most effective lipoprotein apheresis methods, for reduction of lipoprotein(a), Liposorber D. Data on the influence of these lipoprotein apheresis methods on parameters of the coagulation system (prothrombin time, international normalized ratio, activated partial thromboplastin time, fibrinogen) are also reported. The histories of three patients who have been switched to several lipoprotein apheresis methods are given as examples. The major reason for switching was the low efficiency of a given lipoprotein apheresis method with respect to lowering of LDL cholesterol; the reason for this phenomenon was not clear in each case. In three patients who took an oral anticoagulant and were treated with HELP, the influence on the coagulation system is reported; they were submitted to another apheresis method. In two patients we observed an allergy to heparin-they were then treated with a heparin-free apheresis method. In conclusion, we point out that there are several reasons why an apheresis center should offer more than one lipoprotein apheresis method.
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23551674     DOI: 10.1111/j.1744-9987.2012.01129.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  4 in total

1.  Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.

Authors:  Agnieszka Mickiewicz; Justyna Borowiec-Wolna; Witold Bachorski; Natasza Gilis-Malinowska; Rafał Gałąska; Grzegorz Raczak; Magdalena Chmara; Bartosz Wasąg; Miłosz J Jaguszewski; Marcin Fijałkowski; Marcin Gruchała
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

Review 2.  [Lipoprotein apheresis : State of the art and case report of the longest HELP treatment worldwide].

Authors:  Adrienn Tünnemann-Tarr; Julius Ludwig Katzmann; Joachim Thiery; Ulrich Laufs
Journal:  Herz       Date:  2022-04-22       Impact factor: 1.443

Review 3.  Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection.

Authors:  Ulrich Julius
Journal:  Med Devices (Auckl)       Date:  2016-10-13

Review 4.  Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients.

Authors:  Ulrich Julius
Journal:  J Cardiovasc Dev Dis       Date:  2018-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.